-
FDA Grants Priority Review to AstraZeneca and Daiichi Sankyo’s Enhertu for First-Line HER2-Positive Metastatic Breast Cancer
26 Sep 2025 19:32 GMT
… .S. Food and Drug Administration (FDA) has accepted their … trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment … serious conditions with unmet medical needs. HER2-positive … DESTINY-Breast09 Phase III trial, which showed that …
-
Pharmac proposes funding five medicines and more convenient treatment options to ease pressure on health services
26 Sep 2025 16:22 GMT
… ,” says Pharmac’s Acting Director Pharmaceuticals, Caroline De Luca. “We estimate … on infusion services and make treatment more convenient - meaning people … intravenous (IV) infusion medicine for multiple sclerosis.
Pertuzumab with trastuzumab (Phesgo) - …
-
Pharmaceutical Executive Daily: September 25, 2025
25 Sep 2025 23:27 GMT
… Hengrui, Harmony Biosciences’ trial setback for Zygel, and … Pharma for trastuzumab rezetecan, a next-generation antibody-drug conjugate. … from a late-stage trial evaluating Zygel (cannabidiol gel … Thanks for listening to Pharmaceutical Executive Daily. For more …
-
<![CDATA[FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Breast Cancer]]>
25 Sep 2025 20:47 GMT
… by the FDA for the first-line treatment of adult … III DESTINY-Breast11 trial (NCT05113251) for the treatment of patients … References
1. ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted … Breast Cancer. Applied Clinical Trials. May 7, 2025. …
-
Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China
25 Sep 2025 14:07 GMT
… cancer. While randomized trials provide high-level evidence … and Technology Innovation Medical Development Foundation Key … FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment … al. The DEBBRAH trial: trastuzumab deruxtecan in HER2-positive …
-
Business News | Hetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India
25 Sep 2025 11:18 GMT
… trastuzumab and chemotherapy. Despite its proven efficacy, the high cost of treatment … 39;s leading pharmaceutical companies, delivering high-quality medicines across oncology, … as professional medical advice. Always consult your doctor before taking …
-
More pain ahead for Glenmark Pharma? 3 reasons why Nomura sees 25% downside after licencing deal for cancer drug
25 Sep 2025 05:54 GMT
… ’ rating on Glenmark Pharmaceuticals, with a target price … Trastuzumab Rezetecan, which is an oncology ADC (antibody drug conjugate) drug … Hengrui.
Coming back to Trastuzumab Rezetecan – According to … three years for clinical trials and registration. That …
-
China’s Hengrui gets boost from fifth drug-licensing deal of year
25 Sep 2025 05:33 GMT
… in Jiangsu Hengrui Pharmaceuticals, China’s largest drug maker by market … of Mumbai-based Glenmark Pharmaceuticals, it said in a … develop and commercialise trastuzumab rezetecan, a cancer drug that was … Soviet republic nations. The drug also has the potential …
-
Glenmark Pharma shares in focus on $1.1 billion deal for oncology drug
25 Sep 2025 04:34 GMT
… million to Hengrui. The Chinese drugmaker will also be eligible for … and Managing Director of Glenmark Pharmaceuticals. “This collaboration fits well with … address areas of significant unmet medical need.”
Trastuzumab Rezetecan, developed in-house …
-
Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
25 Sep 2025 03:31 GMT
… Drug Administration (FDA) grants Priority Review to applications for medicines … said: “The DESTINY-Breast09 trial showed that treating patients … ], trastuzumab and pertuzumab) as a 1st-line treatment in … 47;or DESTINY-Lung05 trials. Continued approval in China …
About
© 1995-2025